In fact, in some cases, BCL-2 expression correlates with improved clinical outcome, for example in patients with Estrogen Receptor (ER)- and Progesterone Receptor (PR)-positive breast cancer who received adjuvant endocrine therapy [49,50]. Here, ESR1 is linked to breast carcinoma.